Clinical Pathways

Researchers examining how well integrated practice units (IPU) are implemented across 7 cancer centers in Europe found there was no clear, consistent strategy for developing and implementing IPUs, in an analysis that focused mostly on breast cancer clinical pathways.

Twice-yearly magnetic resonance imaging (MRI) scans to find early breast cancers in women with a high genetic risk are more effective than 1 mammogram, study says.

The National Comprehensive Cancer Network (NCCN) released this week new treatment guidelines for patients for 2 uterine cancers, endometrial cancer, the most common gynecologic cancer, and a rare cancer called uterine sarcoma.

A team of multi-institutional clinicians and scientists have recently published the first-ever guidelines for the evaluation and treatment of perimenopausal depression, endorsed by the International Menopause Society, in Menopause and the Journal of Women’s Health.

A new study found no differences in long-term outcomes associated with 2 different approaches to administering trastuzumab (Herceptin) with neoadjuvant chemotherapy in patients with HER2-positive breast cancer. Receiving the combination sequentially rather than concurrently eliminates the known cardiac toxicities associated when chemotherapy and HER2 therapy are given at the same time, researchers said.

A recent review of nearly 582,000 heart attack cases over the span of 19 years found that female patients had a significantly higher survival rate when treated by a female physician in the emergency department.

Earlier this month, the National Comprehensive Cancer Network (NCCN) released new treatment guidelines for a group of rare cancers that impact women during pregnancy.

What type of cervical cancer screening should a woman get, if any, and how often? The latest recommendation from the United States Preventive Services Task Force (USPSTF) said Tuesday that it depends on a woman’s age and other factors.

A recent study found that the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib extended progression-free survival (PFS) and improved quality of life over chemotherapies for patients with metastatic human epidermal growth factor 2-negative breast cancer and mutations in the BRCA 1/2 genes.

A web-based teaching conference was found to be an effective teaching model to improve adherence to clinical pathway guidelines in a large radiation oncology network looking to improve compliance with dosimetric parameters in whole breast irradiation, according to a report published earlier this year.

Researchers recently evaluated data collected from a lung cancer screening program at the University of Illinois at Chicago (UIC) and compared results to the national lung cancer screening guidelines.

Patients with ductal carcinoma in situ (DCIS) are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from this noninvasive form of breast cancer. A new study published Friday said that the combination of the 2 treatments was associated with a small benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone.

Complementary medicine and alternative medicine (CAM) is estimated to be a multibillion business in the United States, but people who use it instead of conventional cancer treatment have a 2-fold risk of death, a recent study in JAMA Oncology reported. Patients using or considering CAM are unlikely to discuss it with their doctors, who should proactively inform patients of the risk, the study said.

The Dana-Farber Cancer Institute recently announced that it is partnering with Royal Philips in order to establish and provide improved clinical pathways in cancer care.

In a recent study, researchers looked to determine whether a symptom and psychosocial collaborative care intervention would improve heart failure–specific health status, depression, and symptom burden in patients with heart failure.

A study of over 35,000 women with early-stage breast cancer found that where you live makes a difference in terms of what kind of posttreatment imaging is received, due to geographic variation.

A solution has been found to maintain a version of a free government website that has hosted clinical guidelines, but now users will have to pay for access.

The FDA has expanded its approval of ribociclib (Kisqali) to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer under 2 new pilot programs to make the development and review of cancer drugs more efficient.

A new study published in JAMA reviewed the premarket development and review times of drugs approved between 2012 and 2017 that were granted Breakthrough Therapy designation and found that the crucial studies that supported these approvals lacked key features, including randomization, double-blinding, and control groups.